Tonix Pharmaceuticals Q3 2025 Preliminary Financial Results

Tonix Pharmaceuticals Holding Corp. disclosed preliminary financial results for the quarter ended September 30, 2025. The company reported $190.1 million in cash and cash equivalents, with 11,475,491 shares of common stock outstanding as of October 24, 2025. Net cash used in operating activities was $28.8 million, compared to $18.8 million in the same quarter of 2024. Capital expenditures were $1.0 million, up from $0 million in the prior year. The net loss for the quarter was $32.0 million, compared to $14.2 million in Q3 2024. Net revenue from product sales increased to $3.3 million from $2.8 million in the previous year. The company believes its cash resources and recent equity offering proceeds will sustain operations into Q1 2027. The preliminary results are subject to revision and should not be considered final. The company expects to file its Quarterly Report on Form 10-Q by November 10, 2025. Additionally, Tonix plans to launch Tonmya™ for fibromyalgia treatment in the U.S. by the end of November 2025.